Impact of Resveratrol and Pharmaceutical Care on Type 2 Diabetes Mellitus and Its Neuropathic Complication: A Randomized Placebo Controlled Clinical Trial

Table 3

Quantitative distribution of pharmaceutical care intervention in the Placebo + PC group.

Component of PC	Subcategories in Placebo + PC	n (%) subcategories	n (%) components of PC
Medication review for identification of DTPs	Indication	25 (13)	61 (31.77)
	Effectiveness	23 (11.97)
	Safety	5 (2.60)
	Compliance	8 (4.61)
Patient education and counseling	Counseling regarding OHA	24 (12.50)	111 (57.81)
	Counseling regarding insulin administration	15 (7.81)
	Counseling regarding hypoglycemic complications	24 (12.5)
	Counseling regarding self-blood glucose monitoring	24 (12.5)
	Counseling regarding foot care	24 (12.5)
Partnership with other health professionals	Referral to specialist nurse	2 (1.04)	20 (10.41)
	Communicate with physicians	14 (7.29)
	Referral to medical advice	4 (2.083)
Total		192 (100)	192 (100)

Values are expressed as number and percentage n (%). DTP, drug therapy problem; PC, pharmaceutical care; Resv, resveratrol; OHA, oral hypoglycemic agent.